Cambridge Investment Research Advisors’s Acurx Pharmaceuticals ACXP Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,000	Closed	-$74K	–	4044
2026 Q1	$74K	Buy	+20,000	New	+$56.7K	﹤0.01%	3818
2025 Q3	–	Sell	-4,250	Closed	-$43K	–	3715
2025 Q2	$43K	Buy	4,250 +3,500	+467%	+$28.2K	﹤0.01%	3548
2025 Q1	$6K	Sell	750 -138	-16%	-$1.86K	﹤0.01%	3488
2024 Q4	$14K	Buy	+888	New	+$26.7K	﹤0.01%	3435
2024 Q3	–	Sell	-500	Closed	-$23K	–	3410
2024 Q2	$23K	Hold	500	–	–	﹤0.01%	3257
2024 Q1	$25K	Buy	+500	New	+$32.5K	﹤0.01%	3254

Other funds holding ACXP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

PFS

Prospect Financial Services Melville, New York $197M AUM 24.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Cambridge Investment Research Advisors's ACXP Position: Q2 2026 in Review

Cambridge Investment Research Advisors sold out of Acurx Pharmaceuticals (ACXP) in Q2 2026, closing a stake of 20,000 shares — an estimated $74K sold.

Cambridge Investment Research Advisors first reported a position in ACXP in Q1 2024 and held it in 6 quarters. The position peaked at $74K in Q1 2026. 19 funds tracked by Wall St. Rank hold ACXP as of Q2 2026.

Cambridge Investment Research Advisors reported no remaining Acurx Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Cambridge Investment Research Advisors sold 20,000 Acurx Pharmaceuticals shares in Q2 2026, an estimated $74K.
Cambridge Investment Research Advisors first reported a position in Acurx Pharmaceuticals in Q1 2024 and held it in 6 quarters.
Cambridge Investment Research Advisors's Acurx Pharmaceuticals position peaked at $74K in Q1 2026.
19 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.